Skip to main content area

NICE asthma guidance

There are important differences between new NICE recommendations on asthma treatment and current “standard practice” in the UK.

For example, NICE NG 80 recommends an early 4-8 week trial of montelukast plus low dose ICS if newly diagnosed asthma is not controlled by a low dose ICS inhaler alone. An ICS (low dose)/LABA combination is only recommended if that trial is unsuccessful – with a trial of maintenance and reliever therapy (MART) regimen recommended BEFORE considering any increase in ICS dose.

Yet more change in the world of respiratory medicine.